Lineage Cell Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Lineage Cell Therapeutics, Inc. (LCTX) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $32.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Intangible Assets › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2023-11-09
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $32.00K.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $65.00K.
- 2023-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $97.00K.
- 2022-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $32.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2023-09-30 | $32.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $65.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $97.00K 10-Q · filed 2023-05-11 |
| 2022-09-30 | $32.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $65.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $97.00K 10-Q · filed 2022-05-12 |
| 2021-09-30 | $32.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |